{"id": "367879", "url": "https://fevir.net/resources/ResearchStudy/367879", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/study-registry-record"], "versionId": "32", "lastUpdated": "2025-09-13T13:13:52.273Z"}, "name": "NCT03640312_FHIR_Transform", "site": [{"type": "Location", "reference": "#NCT03640312-Location-0"}, {"type": "Location", "reference": "#NCT03640312-Location-1"}], "label": [{"type": {"coding": [{"code": "official", "system": "http://hl7.org/fhir/title-type", "display": "Official title"}]}, "value": "A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA)"}, {"type": {"coding": [{"code": "acronym", "system": "http://hl7.org/fhir/title-type", "display": "Acronym"}]}, "value": "QUARTET USA"}], "phase": {"coding": [{"code": "phase-2", "system": "http://terminology.hl7.org/CodeSystem/research-study-phase", "display": "Phase 2"}]}, "title": "Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension", "citeAs": "Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367879. Revised 2025-09-13. Available at: https://fevir.net/resources/ResearchStudy/367879. Computable resource at: https://fevir.net/resources/ResearchStudy/367879#json.", "result": [{"type": "Composition", "display": "Results Section for NCT03640312", "reference": "Composition/367880", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312 Results Report", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "status": "active", "keyword": [{"text": "Hypertension"}, {"text": "Blood Pressure"}], "condition": [{"text": "Hypertension"}], "contained": [{"id": "NCT03640312-drug------quartet-ldqt", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "name": "NCT03640312_drug______quartet_ldqt", "title": "QUARTET LDQT", "status": "active", "handling": "boolean", "classifier": [{"text": "Intervention Type: DRUG"}], "description": "Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.", "resourceType": "EvidenceVariable"}, {"id": "NCT03640312-drug------candesartan", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "name": "NCT03640312_drug______candesartan", "title": "Candesartan", "status": "active", "handling": "boolean", "classifier": [{"text": "Intervention Type: DRUG"}], "description": "Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.", "resourceType": "EvidenceVariable"}, {"id": "NCT03640312-comparison-group-0", "code": {"text": "Experimental"}, "title": "NCT03640312 Comparison Group: QUARTET LDQT", "status": "active", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: [System]-to-FEvIR Converter"}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-comparison-group-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "description": "Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.", "resourceType": "Group", "characteristic": [{"code": {"text": "Exposed to"}, "exclude": false, "valueReference": {"type": "EvidenceVariable", "display": "Drug: QUARTET LDQT", "reference": "#NCT03640312-drug------quartet-ldqt"}}]}, {"id": "NCT03640312-comparison-group-1", "code": {"text": "Active Comparator"}, "title": "NCT03640312 Comparison Group: Candesartan", "status": "active", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: [System]-to-FEvIR Converter"}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-comparison-group-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "description": "Patients randomized to the comparison arm will take a once daily 8mg candesartan.", "resourceType": "Group", "characteristic": [{"code": {"text": "Exposed to"}, "exclude": false, "valueReference": {"type": "EvidenceVariable", "display": "Drug: Candesartan", "reference": "#NCT03640312-drug------candesartan"}}]}, {"id": "NCT03640312-ResponsibleParty-0", "code": [{"text": "Professor of Medicine and Global Health Center Co-Director"}], "organization": {"display": "Washington University School of Medicine"}, "practitioner": {"display": "Mark Huffman"}, "resourceType": "PractitionerRole"}, {"id": "NCT03640312-Location-0", "name": "ACCESS Martin T. Russo Family Health Center", "address": {"city": "Bloomingdale", "state": "Illinois", "country": "United States", "postalCode": "60108"}, "position": {"latitude": 41.95753, "longitude": -88.0809}, "resourceType": "Location"}, {"id": "NCT03640312-Location-1", "name": "Ashland Family Health Center", "address": {"city": "Chicago", "state": "Illinois", "country": "United States", "postalCode": "60609"}, "position": {"latitude": 41.85003, "longitude": -87.65005}, "resourceType": "Location"}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}}], "objective": [{"type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Primary"}]}, "outcomeMeasure": [{"name": "Change in Mean Systolic Blood Pressure", "type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Primary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367882", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-primaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change (from baseline) in automated office systolic blood pressure adjusted for baseline values."}]}, {"type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "outcomeMeasure": [{"name": "Mean Systolic Blood Pressure", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367883", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean automated office systolic blood pressure adjusted for baseline values."}, {"name": "Change in Mean Diastolic Blood Pressure", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367884", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change (from baseline) in automated office diastolic blood pressure adjusted for baseline values."}, {"name": "Mean Diastolic Blood Pressure", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367885", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean automated office diastolic blood pressure adjusted for baseline values."}, {"name": "Proportion of Patients With Hypertension Control", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367886", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Proportion of patients with hypertension control (percent with SBP \\< 130 mmHg and DBP \\<80 mmHg)."}, {"name": "Number of Patients Requiring Step up Treatment", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367887", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Number of patients requiring step-up treatment."}, {"name": "Proportion of Patients With Adverse Event Free Hypertension Control", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367888", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-5", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Proportion of patients with adverse event free hypertension control (percent with SBP \\< 130 mmHg and DBP \\<80 mmHg)."}, {"name": "Medication Adherence", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367889", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Medication adherence defined by objective pill counts"}, {"name": "Health-related Quality of Life", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367890", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-7", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change (from baseline) in health-related quality of life using Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health instrument. PROMIS Global Health is a gauge of general health-care related quality of life. Possible PROMIS Global Physical Health and Global Mental Health scores range from 0-20, with 20 indicating best possible state of health. Raw scores are converted to T-scores to compare to a standardized population. A PROMIS T-score of 50 represents the mean of the population (SD = 10). Higher values here also indicate better health. A positive change in T score, as reported in this outcome measure, would represent an improvement in Global Physical Health or Global Mental Health at 12 weeks compared to baseline."}, {"name": "Change in Mean Systolic Blood Pressure", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367891", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-8", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change (from baseline) in automated office systolic blood pressure adjusted for baseline values."}]}, {"type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "outcomeMeasure": [{"name": "Percentage of Participants With Serious Adverse Events (SAEs)", "type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367896", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Percentage of participants with any Serious Adverse Events (SAE) according to Good Clinical Practice definition: adverse events that result in death, are life threatening, require hospitalization or prolong existing hospitalization, result in persistent disability, result in congenital anomaly or birth defect, or unimportant medical event that requires intervention to prevent any of the above."}, {"name": "Percentage of Participants With Potentially Related Adverse Events", "type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367897", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Percentage of participants with occurrence of any potentially related adverse event (pre-specified as in study procedures). Defined as: At least possibly related to study drug."}, {"name": "Rate of Adverse Events of Special Interest", "type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367898", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Rate of pre-specified adverse events that are known side effects of active ingredients at the participant level."}, {"name": "Mean Change in Serum Potassium", "type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367899", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change (from baseline) in continuous serum potassium."}, {"name": "Mean Change in Serum Sodium", "type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367900", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change (from baseline) in continuous serum sodium."}, {"name": "Mean Change in Blood Urea Nitrogen", "type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367901", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-5", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change (from baseline) in continuous blood urea nitrogen."}, {"name": "Mean Change in Serum Creatinine", "type": {"coding": [{"code": "exploratory", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Exploratory"}]}, "endpoint": {"type": "EvidenceVariable", "reference": "EvidenceVariable/367902", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Mean change in continuous serum creatinine."}]}], "relatesTo": [{"type": "transforms", "targetUri": "https://clinicaltrials.gov/api/v2/studies/NCT03640312?format=json"}, {"type": "transformed-with", "targetAttachment": {"url": "https://fevir.net/resources/Project/29885", "title": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}}, {"type": "cites", "targetMarkdown": "Baldridge AS, Huffman MD, Lazar D, Abbas H, Flowers FM, Quintana A, Jackson A, Khan SS, Chopra A, Vu M, Tripathi P, Jacobson T, Sanuade OA, Kandula NR, Persell SD, Paparello JJ, Rosul LL, Mejia J, Lloyd-Jones DM, Chow CK, Ciolino JD. Efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA): Rationale and design for a randomized controlled trial. Am Heart J. 2022 Dec;254:183-193. doi: 10.1016/j.ahj.2022.09.004. Epub 2022 Sep 15. PMID: 36116516; PMCID: PMC10236716."}, {"type": "documentation", "targetAttachment": {"url": "https://cdn.clinicaltrials.gov/large-docs/12/NCT03640312/Prot_001.pdf", "size": "292795", "title": "ProtStudy Protocol", "creation": "2022-04-20", "contentType": "application/pdf"}}, {"type": "documentation", "targetAttachment": {"url": "https://cdn.clinicaltrials.gov/large-docs/12/NCT03640312/SAP_002.pdf", "size": "300936", "title": "SAPStatistical Analysis Plan", "creation": "2022-02-09", "contentType": "application/pdf"}}, {"type": "documentation", "targetAttachment": {"url": "https://cdn.clinicaltrials.gov/large-docs/12/NCT03640312/ICF_000.pdf", "size": "311884", "title": "ICFInformed Consent Form", "creation": "2020-08-13", "contentType": "application/pdf"}}], "classifier": [{"text": "IPDSharing: Yes"}, {"text": "IPDSharingDescription: Individual participant data will be shared through NHLBI BioLINCC."}, {"text": "IPDSharingInfoType: Study Protocol"}, {"text": "IPDSharingInfoType: Statistical Analysis Plan (SAP)"}, {"text": "IPDSharingInfoType: Informed Consent Form (ICF)"}, {"text": "IPDSharingInfoType: Clinical Study Report (CSR)"}, {"text": "IPDSharingInfoType: Analytic Code"}, {"text": "IPDSharingTimeFrame: Data will be available within 1 year of study conclusion."}, {"text": "IPDSharingAccessCriteria: Access to study data will be managed through NHLBI BioLINCC"}, {"text": "Has Results: True"}, {"text": "Oversight Classifier: oversightHasDmc True"}, {"text": "Oversight Classifier: isFdaRegulatedDrug True"}, {"text": "Oversight Classifier: isFdaRegulatedDevice False"}, {"text": "AgreementPISponsorEmployee: False"}, {"text": "AgreementRestrictiveAgreement: False"}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "367879", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"use": "official", "value": "NCT03640312", "system": "https://clinicaltrials.gov"}, {"value": "202203097-STU00205834", "assigner": {"display": "Washington University School of Medicine"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312 FHIR Transform", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "description": "This trial will investigate whether initiating treatment with ultra-low-dose quadruple-combination therapy (LDQT; including candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) will lower automated office blood pressure and 24-hour ambulatory blood pressure at 12 weeks more effectively, and with no increase in side effects, compared to initiating standard dose monotherapy (candesartan 8 mg) in adults with raised blood pressure (SBP\\>130 mmHg or DBP\\>80 mmHg) and without cardiovascular disease. Our preliminary data from a short-term (4-week) crossover trial of 18 participants suggest that LDQT lowers office blood pressure by 22/13 mmHg on average compared with placebo with no difference in serious adverse events. Effects on 24-hour ambulatory blood pressure were similar.\n\nThe investigators will perform this phase II, single site, randomized controlled trial in a network of federally qualified health centers in Chicago because this population bears a disproportionate burden of blood pressure related diseases, and the investigators have previously successfully conducted clinical studies in this population.\n\nWhile the investigators hypothesize this intervention will be easily implemented and efficacious for all patients and clinicians, the investigators will explore variation in treatment effect by potential moderating variables, including age, sex, race/ethnicity, and health literacy level. Beyond examining efficacy, the investigators also plan to assess feasibility of implementing this intervention in a clinical setting by simultaneously evaluating implementation outcomes of acceptability, preferences, and lessons of LDQT among patients and clinicians.", "recruitment": {"eligibility": {"type": "Group", "display": "NCT03640312 Eligibility Criteria", "reference": "Group/367881", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312 Eligibility Criteria", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "actualNumber": 62}, "studyDesign": [{"text": "Design Masking: Quadruple"}, {"coding": [{"code": "SEVCO:01060", "system": "https://fevir.net/sevco", "display": "Blinding of study participants"}]}, {"coding": [{"code": "SEVCO:01061", "system": "https://fevir.net/sevco", "display": "Blinding of intervention providers"}]}, {"coding": [{"code": "SEVCO:01063", "system": "https://fevir.net/sevco", "display": "Blinding of data analysts"}]}, {"coding": [{"code": "SEVCO:01062", "system": "https://fevir.net/sevco", "display": "Blinding of outcome assessors"}]}, {"coding": [{"code": "SEVCO:01003", "system": "https://fevir.net/sevco", "display": "randomized assignment"}]}, {"coding": [{"code": "SEVCO:01011", "system": "https://fevir.net/sevco", "display": "Parallel cohort design"}]}, {"coding": [{"code": "SEVCO:01001", "system": "https://fevir.net/sevco", "display": "interventional research"}]}], "resourceType": "ResearchStudy", "progressStatus": [{"state": {"coding": [{"code": "completed", "system": "http://hl7.org/fhir/research-study-status", "display": "Completed"}]}}, {"state": {"coding": [{"code": "overall-study", "system": "http://hl7.org/fhir/research-study-status", "display": "Overall study"}]}, "actual": true, "period": {"end": "2024-07-31", "start": "2019-08-30"}}], "associatedParty": [{"name": "Washington University School of Medicine", "role": {"coding": [{"code": "sponsor", "system": "http://hl7.org/fhir/research-study-party-role", "display": "Sponsor"}]}, "classifier": [{"text": "OTHER"}]}, {"name": "Mark Huffman", "role": {"coding": [{"code": "primary-investigator", "system": "http://hl7.org/fhir/research-study-party-role", "display": "Principal investigator"}]}, "party": {"type": "PractitionerRole", "reference": "#NCT03640312-ResponsibleParty-0"}}, {"name": "Washington University School of Medicine", "role": {"coding": [{"code": "lead-sponsor", "system": "http://hl7.org/fhir/research-study-party-role", "display": "Lead sponsor"}]}, "classifier": [{"text": "OTHER"}]}, {"name": "ACCESS Community Health Network", "role": {"coding": [{"code": "collaborator", "system": "http://hl7.org/fhir/research-study-party-role", "display": "Collaborator"}]}, "classifier": [{"text": "OTHER"}]}, {"name": "University of Sydney", "role": {"coding": [{"code": "collaborator", "system": "http://hl7.org/fhir/research-study-party-role", "display": "Collaborator"}]}, "classifier": [{"text": "OTHER"}]}, {"name": "Mark D Huffman, PhD, MD", "role": {"coding": [{"code": "primary-investigator", "system": "http://hl7.org/fhir/research-study-party-role", "display": "Principal investigator"}]}, "party": {"display": "Northwestern University Feinberg School of Medicine"}}, {"name": "Jody D Ciolino, PhD", "role": {"coding": [{"code": "primary-investigator", "system": "http://hl7.org/fhir/research-study-party-role", "display": "Principal investigator"}]}, "party": {"display": "Overall Study Officials:"}}], "comparisonGroup": [{"eligibility": {"type": "Group", "display": "QUARTET LDQT: Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.", "reference": "#NCT03640312-comparison-group-0"}}, {"eligibility": {"type": "Group", "display": "Candesartan: Patients randomized to the comparison arm will take a once daily 8mg candesartan.", "reference": "#NCT03640312-comparison-group-1"}}], "descriptionSummary": "To investigate, in a double-blind randomized controlled trial, whether initiating treatment with ultra-low-dose quadruple-combination therapy (\"LDQT\") will lower office blood pressure more effectively, and with fewer side effects, compared to initiating standard dose monotherapy as per current guidelines in patients with hypertension.\n\nPrimary hypothesis: A combination pill comprising four types of blood pressure lowering medications, each at one-quarter standard doses, will lower office blood pressure more effectively than initiating patients with standard dose monotherapy as per contemporary clinical practice guideline recommendations.", "primaryPurposeType": {"coding": [{"code": "treatment", "system": "http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type", "display": "Treatment"}]}}